Home › Lilly announces detailed results from two Phase III studies testing...
 

Keywords :   


Lilly announces detailed results from two Phase III studies testing...

2014-06-18 12:50:18| Biotech - Topix.net

Eli Lilly and Company has released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with a lower risk for hypoglycemia .1,2 Dulaglutide is an investigational glucagon-like peptide-1 receptor agonist being studied for ... (more)

Tags: results iii studies detailed

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
05.07Simplestream reveals preferred technology partnership with Freely
More »